Earnings Call · Q2 FY2022·2022-08-03

Q2 22EPS +16.70%·Rev n/aQ1 22EPS +52.67%·Rev n/aQ4 21EPS +14.04%·Rev n/aQ3 21EPS -18.26%·Rev n/a⚠ consensus missing

Moderna, Inc. MRNA

Lavina Talukdar — Head of Investor Relations

Stephane Bancel — Chief Executive Officer

Paul Burton — Chief Medical Officer

Stephen Hoge — President

Arpa Garay — Chief Commercial Officer

David Meline — Chief Financial Officer

+16.0%1d on move date+14.4% vs SPY3d+16.2%5d+6.4%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MRNA calls or request research access.

More MRNA calls Browse calls Request research access